Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 5/20 | 0.37 |
| ▸ | CTSC | P53634 | 4/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.35 |
| ▸ | GSK3A | P49840 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17023724 | 0.89 | CFD (0.42) | CFDCTSCCHRM2CHRM1CHRM3 | |
| SCHEMBL29545547 | 0.89 | CFD (0.42) | CFDCTSCCHRM2CHRM1CHRM3 | |
| SCHEMBL18555502 | 0.89 | CFD (0.42) | CFDCTSCCHRM2CHRM1CHRM3 | |
| SCHEMBL18576565 | 0.89 | CFD (0.42) | CFDCTSCCHRM2CHRM1CHRM3 | |
| SCHEMBL17053073 | 0.89 | CFD (0.42) | CFDCTSCCHRM2CHRM1CHRM3 | |
| SCHEMBL17031918 | 0.88 | CTSC (0.36) | CFDCTSC | |
| Hydrochloric Acid SCHEMBL17049108 | 0.88 | ALOX15 (0.36) | CTSCCHRM2CHRM1CHRM3GSK3A | |
| Hydrochloric Acid SCHEMBL17023497 | 0.88 | CFD (0.41) | CFDCTSCCHRM2CHRM1CHRM3 | |
| Hydrochloric Acid SCHEMBL29544869 | 0.88 | CFD (0.41) | CFDCTSCCHRM2CHRM1CHRM3 | |
| Hydrochloric Acid SCHEMBL17046887 | 0.88 | CFD (0.41) | CFDCTSCCHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9828396-B2 | Alkyne compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| WO-2015130784-A1 | ALKYNE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-09-03 | — | — | WO | disclosed |
| US-20150239868-A1 | Alkyne Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239868-A1 | Alkyne Compounds for Treatment of Complement Mediated Disorders | CFD, C9, TFPI | CFD 1/4885CTSC 1113/4885CHRM2 1152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.